The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes
- Carrai P
- Morelli C
- Cordone G
- Romano A
- Tamé M
- Lionetti R
- Pietrosi G
- Lenci I
- Piai G
- Russo FP
- Coppola C
- Melazzini M
- Montilla S
- Pani L
- Petraglia S
- Russo P
- Trotta MP
- Martini S
- Toniutto P
- ITACOPS study group (Bandiera F
- Bhoori S
- Brillanti S
- Burra P
- Corsale S
- De Luca A
- Fagiuoli S
- Fattovich G
- Fava G
- Felder M
- Forte P
- Galeota-Lanza A
- Gitto S
- Grieco A
- Grossi P
- Ialungo AM
- Iemmolo RM
- Loiacono L
- Mangia A
- Merli M
- Piacentini A
- Pellicelli A
- RIGAMONTI C
- Gabriella V
- Zignego AL
DOIAbstract
Direct antivirals are available for treating recurrent hepatitis C (RHC). This study reported outcomes of 424 patients with METAVIR F3-F4 RHC who were treated for 24 weeks with sofosbuvir/ribavirin and followed for 12 weeks within the Italian sofosbuvir compassionate use program. In 55 patients, daclatasvir or simeprevir were added. Child-Pugh class and model of end stage liver disease (MELD) scores were evaluated at baseline and 36 weeks after the start of therapy. The sustained viral response (SVR) was 86.7% (316/365) in patients who received sofosbuvir/ribavirin and 98.3% (58/59) in patients who received a second antiviral (P < 0.01). In patients treated with sofosbuvir/ribavirin, a significant difference in SVR was observed between pati...
Add to ORKG